HC Wainwright & Co. reiterates Buy rating on Immunocore Holdings, $100 price target

HC Wainwright & Co. maintained a Buy rating on Immunocore Holdings with a $100 price target, suggesting a 222.8% upside from the Oct 23 close of $30.98. The firm cited the company's strong pipeline, upcoming data releases, and established commercial footprint as key reasons for the rating.

Original reporting
Published Oct 26, 2026, 5:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 5:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. reiterates Buy rating on Immunocore Holdings, $100 price target — source image
Decision brief

The 30-second read

$IMCRBullishLow
01

Why it matters

The trading relevance is primarily sentiment and positioning around analyst expectations, not a fresh fundamental datapoint like trial results, approvals, or updated guidance.

02

Market read

For traders, the actionable element is the reiterated bullish target and catalyst narrative, which may marginally support the stock but lacks a new company-specific disclosure.

03

What to watch

Execution risk remains high for clinical-stage programs; the note’s emphasis on late-2026 data does not address probability of success, timelines, or competitive dynamics.

Relevance 4/10Novelty 3/10Timing: as of the analyst note publication date, for positioning ahead of late-2026 clinical data

Background

The piece summarizes an HC Wainwright & Co analyst note reiterating a Buy rating for Immunocore and reiterating a $100 price target, with emphasis on its pipeline and KIMMTRAK/brenetafusp development.

Company-level read

Ticker impact

$IMCRBullishMedium confidence
Context

HC Wainwright reiterates a Buy on Immunocore and sets a $100 price target, citing pipeline strength and late-2026 data catalysts.

Expected impact

Likely modest upward bias as traders price in the reiterated Buy and target, though follow-through depends on upcoming clinical data.

Evidence & confidence

The article is an analyst note reiteration, not a new trial result, approval, or guidance change; the main incremental input is the reiterated $100 target and thesis framing.

Market effects

Reinforces positive sentiment toward immuno-oncology/biotech pipeline narratives, but without new sector-wide data.

No clear regional macro or cross-market linkage beyond general biotech sentiment.

Limited global impact; the catalyst described is company-specific clinical timing rather than a worldwide regulatory or market event.

Counterpoint

A reiterated rating and price target may have limited incremental value if no new clinical readout or regulatory milestone is disclosed.

Key entities

  • Immunocore Holdings

    Subject of the analyst note reiteration, with a stated $100 price target and pipeline/catalyst thesis.

  • HC Wainwright & Co.

    Brokerage issuing the reiterated Buy rating and price target.

Related articles

$IMCRMed

Immunocore 3Q 2026: Revenue $102.22M, EPS ($0.28) — 10-Q Summary

Immunocore reported a 1.4% YoY revenue decline to $102.22M in Q3 2026, with a widened net loss of $14.22M. U.S. sales fell due to stocking adjustments and fewer sales weeks, partially offset by European and international growth. R&D spending increased, impacting results. KIMMTRAK is approved in 39 countries, and TEBE-AM Phase 3 trial enrollment is complete, with data expected in Q2 2027.